Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.

Khan HY, Ge J, Nagasaka M, Aboukameel A, Mpilla G, Muqbil I, Szlaczky M, Chaker M, Baloglu E, Landesman Y, Mohammad RM, Azmi AS, Sukari A.

Int J Mol Sci. 2019 Dec 29;21(1). pii: E237. doi: 10.3390/ijms21010237.

2.

Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma.

Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al Hallak MN, Tesfaye A, Kim S, Shidham V, Ramzi M, Philip PA.

Clin Cancer Res. 2019 Dec 12. pii: clincanres.1728.2019. doi: 10.1158/1078-0432.CCR-19-1728. [Epub ahead of print]

PMID:
31831564
3.

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.

Mpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS.

Cancers (Basel). 2019 Nov 29;11(12). pii: E1902. doi: 10.3390/cancers11121902.

4.

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.

Sexton R, Mahdi Z, Chaudhury R, Beydoun R, Aboukameel A, Khan HY, Baloglu E, Senapedis W, Landesman Y, Tesfaye A, Kim S, Philip PA, Azmi AS.

Int J Mol Sci. 2019 Sep 28;20(19). pii: E4826. doi: 10.3390/ijms20194826.

5.

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.

Muqbil I, Chaker M, Aboukameel A, Mohammad RM, Azmi AS, Ramchandren R.

Heliyon. 2019 Aug 31;5(8):e02290. doi: 10.1016/j.heliyon.2019.e02290. eCollection 2019 Aug.

6.

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma.

Azmi AS, Li Y, Aboukameel A, Muqbil I, Philip PA, Mohammad RM.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1101. doi: 10.3390/cancers11081101.

7.

KRASG12C inhibitors on the horizon.

Cagir A, Azmi AS.

Future Med Chem. 2019 May;11(9):923-925. doi: 10.4155/fmc-2018-0304. Epub 2019 May 29. No abstract available.

8.

Enhanced Flexibility of Biodegradable Polylactic Acid/Starch Blends Using Epoxidized Palm Oil as Plasticizer.

Awale RJ, Ali FB, Azmi AS, Puad NIM, Anuar H, Hassan A.

Polymers (Basel). 2018 Sep 2;10(9). pii: E977. doi: 10.3390/polym10090977.

9.

Ras and exosome signaling.

Sexton RE, Mpilla G, Kim S, Philip PA, Azmi AS.

Semin Cancer Biol. 2019 Feb;54:131-137. doi: 10.1016/j.semcancer.2019.02.004. Epub 2019 Feb 12. Review.

10.

miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.

Tesfaye AA, Azmi AS, Philip PA.

Am J Pathol. 2019 Jan;189(1):58-70. doi: 10.1016/j.ajpath.2018.10.005. Review.

11.

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.

Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS.

Oncotarget. 2018 Oct 19;9(82):35327-35342. doi: 10.18632/oncotarget.26239. eCollection 2018 Oct 19.

12.

Nuclear export mechanisms of circular RNAs: size does matter.

Azmi AS.

Noncoding RNA Investig. 2018 Sep;2. pii: 52. doi: 10.21037/ncri.2018.08.03. Epub 2018 Sep 14. No abstract available.

13.

Some chinks in RAS armor.

Azmi AS.

Semin Cancer Biol. 2019 Feb;54:iii-iv. doi: 10.1016/j.semcancer.2018.08.005. Epub 2018 Aug 6. No abstract available.

14.

Nuclear Export Inhibition for Pancreatic Cancer Therapy.

Muqbil I, Azmi AS, Mohammad RM.

Cancers (Basel). 2018 May 7;10(5). pii: E138. doi: 10.3390/cancers10050138. Review.

15.

Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.

Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK.

Colloids Surf B Biointerfaces. 2018 Jul 1;167:8-19. doi: 10.1016/j.colsurfb.2018.03.046. Epub 2018 Mar 28.

PMID:
29625422
16.

Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells".

Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH.

Cancer Lett. 2018 Jun 1;423:153. doi: 10.1016/j.canlet.2018.03.020.

17.

Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS.

Expert Opin Ther Targets. 2018 Jan;22(1):9-17. doi: 10.1080/14728222.2018.1413091. Epub 2017 Dec 10. Review.

18.

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM.

Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10.

19.

Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.

Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS.

Small GTPases. 2019 Sep;10(5):367-377. doi: 10.1080/21541248.2017.1329694. Epub 2017 Jun 23.

20.

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.

Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y.

Oncotarget. 2017 Jul 4;8(27):44295-44311. doi: 10.18632/oncotarget.17869.

21.

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS.

Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.

22.

Targeting Cancer at the Nuclear Pore.

Azmi AS, Mohammad RM.

J Clin Oncol. 2016 Dec;34(34):4180-4182. Epub 2016 Oct 23. No abstract available.

PMID:
27863200
23.

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

Muqbil I, Aboukameel A, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D, Zonder J, Azmi AS, Mohammad RM.

Cancer Lett. 2016 Dec 28;383(2):309-317. doi: 10.1016/j.canlet.2016.09.016. Epub 2016 Sep 28.

24.

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.

Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Nov 29;7(48):78883-78895. doi: 10.18632/oncotarget.12428.

25.

The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma.

Diab M, Muqbil I, Mohammad RM, Azmi AS, Philip PA.

J Clin Med. 2016 Jun 16;5(6). pii: E59. doi: 10.3390/jcm5060059. Review.

26.

F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS.

Semin Cancer Biol. 2016 Feb;36:95-104. doi: 10.1016/j.semcancer.2016.01.002. Epub 2016 Jan 21. Review.

27.

Opening a Pandora's (F)-box in cancer.

Azmi AS.

Semin Cancer Biol. 2016 Feb;36:1-2. doi: 10.1016/j.semcancer.2015.12.001. Epub 2015 Dec 17. No abstract available.

PMID:
26706999
28.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

29.

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.

Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM.

Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077.

30.

A multi-targeted approach to suppress tumor-promoting inflammation.

Samadi AK, Bilsland A, Georgakilas AG, Amedei A, Amin A, Bishayee A, Azmi AS, Lokeshwar BL, Grue B, Panis C, Boosani CS, Poudyal D, Stafforini DM, Bhakta D, Niccolai E, Guha G, Vasantha Rupasinghe HP, Fujii H, Honoki K, Mehta K, Aquilano K, Lowe L, Hofseth LJ, Ricciardiello L, Ciriolo MR, Singh N, Whelan RL, Chaturvedi R, Ashraf SS, Shantha Kumara HMC, Nowsheen S, Mohammed SI, Keith WN, Helferich WG, Yang X.

Semin Cancer Biol. 2015 Dec;35 Suppl:S151-S184. doi: 10.1016/j.semcancer.2015.03.006. Epub 2015 May 5. Review.

31.

Broad targeting of resistance to apoptosis in cancer.

Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS.

Semin Cancer Biol. 2015 Dec;35 Suppl:S78-S103. doi: 10.1016/j.semcancer.2015.03.001. Epub 2015 Apr 28. Review.

32.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S.

Semin Cancer Biol. 2015 Dec;35 Suppl:S25-S54. doi: 10.1016/j.semcancer.2015.02.006. Epub 2015 Apr 17. Review.

33.

Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.

Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, Malhotra M, Meeker AK, Amedei A, Amin A, Ashraf SS, Aquilano K, Azmi AS, Bhakta D, Bilsland A, Boosani CS, Chen S, Ciriolo MR, Fujii H, Guha G, Halicka D, Helferich WG, Keith WN, Mohammed SI, Niccolai E, Yang X, Honoki K, Parslow VR, Prakash S, Rezazadeh S, Shackelford RE, Sidransky D, Tran PT, Yang ES, Maxwell CA.

Semin Cancer Biol. 2015 Dec;35 Suppl:S5-S24. doi: 10.1016/j.semcancer.2015.03.005. Epub 2015 Apr 11. Review.

34.

Therapeutic targeting of replicative immortality.

Yaswen P, MacKenzie KL, Keith WN, Hentosh P, Rodier F, Zhu J, Firestone GL, Matheu A, Carnero A, Bilsland A, Sundin T, Honoki K, Fujii H, Georgakilas AG, Amedei A, Amin A, Helferich B, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Niccolai E, Aquilano K, Ashraf SS, Nowsheen S, Yang X.

Semin Cancer Biol. 2015 Dec;35 Suppl:S104-S128. doi: 10.1016/j.semcancer.2015.03.007. Epub 2015 Apr 11. Review.

35.

Cancer prevention and therapy through the modulation of the tumor microenvironment.

Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, Bilsland AE, Boosani CS, Chen S, Ciriolo MR, Crawford S, Fujii H, Georgakilas AG, Guha G, Halicka D, Helferich WG, Heneberg P, Honoki K, Keith WN, Kerkar SP, Mohammed SI, Niccolai E, Nowsheen S, Vasantha Rupasinghe HP, Samadi A, Singh N, Talib WH, Venkateswaran V, Whelan RL, Yang X, Felsher DW.

Semin Cancer Biol. 2015 Dec;35 Suppl:S199-S223. doi: 10.1016/j.semcancer.2015.02.007. Epub 2015 Apr 10. Review.

36.

Tissue invasion and metastasis: Molecular, biological and clinical perspectives.

Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P, Sliva D, Subbarayan PR, Sarkar M, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Ye L, Helferich WG, Yang X, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Nowsheen S, Pantano F, Santini D.

Semin Cancer Biol. 2015 Dec;35 Suppl:S244-S275. doi: 10.1016/j.semcancer.2015.03.008. Epub 2015 Apr 10. Review.

37.

Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS.

Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198. doi: 10.1016/j.semcancer.2015.03.004. Epub 2015 Mar 25. Review.

38.

Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Amin ARMR, Karpowicz PA, Carey TE, Arbiser J, Nahta R, Chen ZG, Dong JT, Kucuk O, Khan GN, Huang GS, Mi S, Lee HY, Reichrath J, Honoki K, Georgakilas AG, Amedei A, Amin A, Helferich B, Boosani CS, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bhakta D, Halicka D, Niccolai E, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Bilsland A, Shin DM.

Semin Cancer Biol. 2015 Dec;35 Suppl:S55-S77. doi: 10.1016/j.semcancer.2015.02.005. Epub 2015 Mar 6. Review.

39.

Broad targeting of angiogenesis for cancer prevention and therapy.

Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith WN, Jensen LD.

Semin Cancer Biol. 2015 Dec;35 Suppl:S224-S243. doi: 10.1016/j.semcancer.2015.01.001. Epub 2015 Jan 16. Review.

40.

p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?

Azmi AS, Mohammad RM.

Future Med Chem. 2015;7(1):5-7. doi: 10.4155/fmc.14.144. No abstract available.

PMID:
25582328
41.

Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers.

Bao B, Azmi AS, Ali S, Zaiem F, Sarkar FH.

Ann Transl Med. 2014 Jun;2(6):59. doi: 10.3978/j.issn.2305-5839.2014.06.05. Review.

42.

Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?

Muqbil I, Wu J, Aboukameel A, Mohammad RM, Azmi AS.

Semin Cancer Biol. 2014 Aug;27:39-45. doi: 10.1016/j.semcancer.2014.06.003. Epub 2014 Jun 17. Review.

43.

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.

Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB, Mohammad RM.

Oncotarget. 2014 Jun 15;5(11):3444-54.

44.

The evolving role of nuclear transporters in cancer.

Azmi AS.

Semin Cancer Biol. 2014 Aug;27:1-2. doi: 10.1016/j.semcancer.2014.04.011. Epub 2014 May 2. No abstract available.

PMID:
24793699
45.

Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer.

Bao B, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Aboukameel A, Mohammad R, Van Buren E, Azmi AS, Sarkar FH.

Stem Cells Dev. 2014 Aug 15;23(16):1947-58. doi: 10.1089/scd.2013.0551. Epub 2014 Jun 6.

PMID:
24734907
46.

Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.

Bao B, Azmi AS, Aboukameel A, Ahmad A, Bolling-Fischer A, Sethi S, Ali S, Li Y, Kong D, Banerjee S, Back J, Sarkar FH.

J Biol Chem. 2014 May 23;289(21):14520-33. doi: 10.1074/jbc.M113.532887. Epub 2014 Apr 9.

47.

Rectifying cancer drug discovery through network pharmacology.

Azmi AS, Mohammad RM.

Future Med Chem. 2014 Apr;6(5):529-39. doi: 10.4155/fmc.14.6.

PMID:
24649956
48.

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.

Al-Hajeili M, Azmi AS, Choi M.

Onco Targets Ther. 2014 Feb 4;7:187-92. doi: 10.2147/OTT.S40705. eCollection 2014. Review.

49.

Regulation of KRAS-PAK4 axis by microRNAs in cancer.

Choudhry ZS, Tripathi V, Sutton M, Bao B, Mohammad RM, Azmi AS.

Curr Pharm Des. 2014;20(33):5275-8. Review.

PMID:
24479809
50.

Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property.

Azmi AS, Sarkar FH, Hadi SM.

F1000Res. 2013 Jun 4;2:135. doi: 10.12688/f1000research.2-135.v1. eCollection 2013.

Supplemental Content

Support Center